Newark, Delaware, March 25, 2019 – With Brexit pending and the European Medicines Agency (EMA) headquarters moving from London to the Netherlands, QPS, a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services, today announced it is ready to take on clinical trials that need to relocate and is prepared to manage new projects in the Netherlands, Austria and around the globe.
According to a recent report by Fitch Solutions, Brexit is already impacting the UK’s clinical trials environment. The number of clinical trials taking place in the UK has declined by more than 25 percent since British voters elected to leave the EU in 2016.
“There are concerns about how medicines will be approved in the UK after Brexit, as well as how MHRA will operate as a stand-alone agency and how the EMA will manage data generated in the UK. As a result, companies are beginning to suspend clinical trial activities across the UK,” said Marc Thouin, President and General Manager, of QPS in the Netherlands. “With full-service research facilities in the Netherlands, Austria and around the globe, QPS is prepared to take on clinical trials that require relocation and manage new research projects.”
The Netherlands is a great location to host a clinical research site, as it is home to a top R&D innovation hub for biopharmaceutical companies, the new EMA headquarters, one of the world’s highest-ranking healthcare systems, several research institutes, and more than 100 biotech companies.
“QPS has the scientists, teams and turn-key facilities needed to take on research projects moving out of the UK,” said Thouin. “Our 51,000 square-foot research facility in the Netherlands has more than 200 people working on the development of new medicines, and QPS has an additional 80 scientists in a nearby research facility in Austria.”
In the Netherlands, QPS specializes in discovery, preclinical and clinical drug development research. This location has completed more than 250 studies, involving more than 13,000 healthy subjects for Phase I clinical trials and more than 500 patients for Phase II studies. Additionally, QPS in the Netherlands has conducted more than 2,000 bioanalysis studies, with more than one million samples analyzed.
In Austria, QPS focuses on discovery, preclinical and clinical drug development research. This location is well-known for its transgenic mouse models, with more than 1,400 transgenic animal studies completed. Scientists in the QPS Austria location have tested thousands of CNS compounds, with many of them moving to late-phase development. Additionally, the Austria location manages Phase II-IV clinical trials, ensuring its sponsors successfully recruit patients for multicenter research studies. The Austria location has managed more than 12,000 subjects involved in its late phase clinical trials.
For QPS insights about the impact of Brexit on preclinical research and bioanalysis, read “Brexit’s Impact on Gene and Cell Therapy, Biosimilars,” written by Zamas Lam, Ph.D., SVP and Global Head of Preclinical Development, QPS, and published in Bioanalysis Zone.
About QPS Holdings, LLC
QPS is a global contract research organization (CRO) providing discovery, preclinical and clinical drug development services since 1995. The company accelerates pharmaceutical breakthroughs across the globe by delivering custom-built research services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. For more information, visit www.qps.com or email email@example.com.
Tel.: +1 314-534-8187